Empowered Funds’s Novavax NVAX Stock Holding History

Empowered Funds’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,969	Closed	-$1.56M	–	275
2021 Q1	$1.56M	Hold	13,969	–	–	0.3%	125
2020 Q4	$1.56M	Buy	+13,969	New	+$1.48M	0.3%	125

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Empowered Funds's NVAX Position: Q2 2021 in Review

Empowered Funds sold out of Novavax (NVAX) in Q2 2021, closing a stake of 13,969 shares — an estimated $1.56M sold.

Empowered Funds first reported a position in NVAX in Q4 2020 and held it in 2 quarters. The position peaked at $1.56M in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Empowered Funds reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Empowered Funds sold 13,969 Novavax shares in Q2 2021, an estimated $1.56M.
Empowered Funds first reported a position in Novavax in Q4 2020 and held it in 2 quarters.
Empowered Funds's Novavax position peaked at $1.56M in Q1 2021.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Empowered Funds's 13F filing for Q2 2021, filed 4 Aug 2021.